Clyde Biosciences, A Leading Drug Toxicity Testing Company, Closes Series A Investment
In All, PortfolioGlasgow, United Kingdom, April 13th 2015 – Clyde Biosciences Ltd. (Clyde Biosciences) has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the…